Evidence map›Paper›PMID 37410972›Full record

ArticleJCO precision oncology2023

Activity of Type II RAF Inhibitor Tovorafenib in a Pediatric Patient With a Recurrent Spindle Cell Sarcoma Harboring a Novel

Katharine Offer, Michael T McGuire, Kunchang Song, Michael J Goldfischer, Monika A Davare, Christopher L Corless, Carol Beadling, Tanaya Neff, Michael C Cox, Sandya Govinda Raju and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Katharine OfferChildren's Cancer Institute, Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ.ORCID 0000-0003-3420-0265
Michael T McGuireDepartment of Radiology, Hackensack Meridian School of Medicine, Hackensack, NJ.
Kunchang SongDepartment of Pathology, Hackensack Meridian Health, Hackensack, NJ.
Michael J GoldfischerDepartment of Pathology, Hackensack Meridian Health, Hackensack, NJ.
Monika A DavareDepartment of Pediatrics, Oregon Health & Science University, Portland, OR.ORCID 0000-0003-1802-7597
Christopher L CorlessKnight Diagnostics Laboratory, Oregon Health & Science University, Portland, OR.
Carol BeadlingSchool of Medicine, Oregon Health & Science University, Portland, OR.ORCID 0000-0001-6444-7782
Tanaya NeffKnight Diagnostics Laboratory, Oregon Health & Science University, Portland, OR.
Michael C CoxDay One Biopharmaceuticals, Brisbane, CA.
Sandya Govinda RajuDay One Biopharmaceuticals, Brisbane, CA.
Samuel C BlackmanDay One Biopharmaceuticals, Brisbane, CA.
Hackensack Meridian Health · USOregon Health & Science University · USNGM Biopharmaceuticals (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Proto-Oncogene Proteins B-rafSarcomaBiomarkers, TumorChildGene FusionHumansNeoplasm Recurrence, LocalPyridinesPyrimidinesSorting NexinsThiazolesBiomarkers, TumorBRAF protein, humanProto-Oncogene Proteins B-rafPyridinesPyrimidinesSNX8 protein, humanSorting NexinsThiazolestovorafenib

Identifiers

PMID37410972
PMCPMC10581647
OpenAlexW4383313278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.